Article information
Abstract
The presence of microorganisms with acquired resistance to multiple antibiotics complicates the management and outcome of critically ill patients. The intensivist, in his/her daily activity, is responsible for the prevention and control of the multiresistance and the challenge of prescribing the appropriate treatment in case of an infection by these microorganisms. We have reviewed the literature regarding the definition, important concepts related to transmission, recommendations on general measures of control in the units and treatment options. We also present data on the situation in our country known primarily through the ENV IN-UCI register. Addressing the multiresistance not only requires training but also teamwork with other specialists and adaptation to the local environment.
Keywords:
Multidrug-resistant organism
Surveillance
Antibiotic therapy
Resumen
La presencia de microorganismos con resistencia adquirida a múltiples antibióticos complica el manejo y la evolución de los pacientes críticos. El intensivista, en su actividad diaria, se enfrenta a este problema desde la responsabilidad de la prevención y control y desde el reto de prescribir el tratamiento antibiótico apropiado ante una posible infección. Se realiza una revisión de la bibliografía en lo concerniente a definición, conceptos importantes relacionados con la transmisión, recomendaciones sobre medidas generales de control en las unidades y opciones de tratamiento. Además se presentan datos epidemiológicos sobre la situación en nuestro país obtenidos, fundamentalmente, a través del ENV IN-UCI. El abordaje de la multirresistencia antibiótica requiere formación adecuada, trabajo en equipo con otros profesionales y conocimiento de la epidemiología local.
Palabras clave:
Microorganismos multirresistentes
Vigilancia epidemiológica
Tratamiento antibiótico
Full text is only aviable in PDF
References
[1.]
J.D. Siegel, E. Rhinehart, M. Jackson, L. Chiarello.
Management of multidrug-resistant organisms in health care settings, 2006.
Am J Infect Control, 35 (2007), pp. S165-S193
[2.]
F. Kollef.
Antibiotic resistance in the Intensive Care Unit.
Ann Intern Med, 134 (2001), pp. 298-314
[3.]
D.A. Goldmann, R.A. Weinstein, R.P. Wenzel, O.C. Tablan, R.J. Duma, R.P. Gaynes, et al.
Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership.
JAMA, 275 (1996), pp. 234-240
[5.]
F.A. Waldvogel.
New resistance in Staphylococcus aureus.
N Engl J Med, 340 (1999), pp. 556-557
[6.]
L.B. Rice.
Controlling antibiotic resistance in the ICU: different bacteria, different strategies.
Cleve Clin J Med, 70 (2003), pp. 793-800
[7.]
R eal Decreto 127/84. Guia de formacion de especialistas. Medicina Intensiva. Available from: http://www.msps.es/profesionales/formacion/docs/Medicina_Intensiva.pdf. [Accessed 2009 Oct 30].
[8.]
J. Rodríguez-Baño, A. Pascual.
Microorganismos multirresistentes ¿adquisición nosocomial o comunitaria?.
Enferm Infecc Microbiol Clin, 22 (2004), pp. 505-506
[9.]
Palomar M, Alvarez-Lerma F, Olaechea P, Insausti J, Lopez-Pueyo MJ. Informe ENVIN 2008. Available from: http://hws.vhebron.net/envin-helics/Help/ENVIN-UCI%20Informe%202008.pdf.
[10.]
F. Álvarez Lerma.
Impacto de las resistencias bacterianas sobre la política de antibiótica.
Med Intensiva, 22 (1998), pp. 17-23
[11.]
M.H. Kollef, G. Sherman, S. Ward, V.J. Fraser.
Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.
Chest, 115 (1999), pp. 462-474
[12.]
E.H. Ibrahim, G. Sherman, S. Ward, V.J. Fraser, M.H. Kollef.
The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.
Chest, 118 (2000), pp. 146-155
[13.]
M. Iregui, S. Ward, G. Sherman, V.J. Fraser, M.H. Kollef.
Clinical importance of delay in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.
Chest, 122 (2002), pp. 262-268
[14.]
C.I. Kang, S.H. Kim, W.B. Park, K.D. Lee, H.B. Kim, E.C. Kim, M.D. Oh, K.W. Choe.
Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome.
Antimicrob Agents Chemother, 49 (2005), pp. 760-766
[15.]
B. Du, Y. Long, H. Liu, D. Chen, D. Liu, Y. Xu, X. Xie.
Extendespectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection risk factors and clinical outcomes.
Intensive Care Med, 28 (2002), pp. 1718-1723
[16.]
Y. Carmeli, N. Troillet, A.W. Karchmer, M.H. Samore.
Arch Intern Med, 159 (1999), pp. 1127-1132
[17.]
M.E. Falagas, I.A. Bliziotis, I.I. Siempos.
Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies.
Crit Care, 10 (2006), pp. R48
[18.]
S.E. Cosgrove, G. Sakoulas, E.N. Perencevich, M.J. Schwaber, A.W. Karchmer, Y. Carmeli.
Comparison of mortality associated with methicillin-resistant an methicillin-susceptible Staphylococcus aureus bacteriemia: a meta-analysis.
Clin Infect Dis, 36 (2003), pp. 53-59
[19.]
S.M. Bhavnani, J.A. Drake, A. Forrest, J.A. Deinhart, R.N. Jones, D.J. Biedenbach, C.H. Ballow.
Diagn Microbiol Infect Dis, 36 (2000), pp. 145-158
[20.]
C. Peña, M. Pujol, C. Ardanuy, A. Ricart, R. Pallarés, J. Liñares, J. Ariza, F. Gudiol.
An oubreak of hospital-acquired Klebsiella pneumoniae bacteraemia, incluidig strains producing extended-spectrum beta-lactamase.
J Hosp Infect, 47 (2001), pp. 53-59
[21.]
S.E. Cosgrove, K.S. Kaye, G.M. Eliopoulous, Y. Carmeli.
Health and economic outcomes of third-generation cephalosporin resistance in Enterobacter species.
Arch Inter Med, 162 (2002), pp. 185-190
[22.]
M.S. Niederman.
Appropriate use of antimicrobial agents: Challenges and strategies for improvement.
Crit Care Med, 31 (2003), pp. 608-616
[23.]
K.B. Kirkland, J.M. Wenstein.
Adverse effects of contact isolation.
Lancet, 354 (1999), pp. 1177-1178
[24.]
K.K. Lai, A.L. Kelley, Z.S. Melvin, P.P. Belliveau, S.A. Fontecchio.
Failure to erradícate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions.
Infect Control Hosp Epidemiol, 19 (1998), pp. 647-652
[25.]
H.T. Stelfox, D.W. Bates, D.A. Redelmeier.
Safety of patients isolated for infection control.
JAMA, 290 (2003), pp. 1899-1905
[26.]
E.A. Bryce, S.M. Tiffin, J.L. Isaac-Renton, C.J. Wright.
Evidence of delay in transferring patients with methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus to long-term-care facilities.
Infect Control Hosp Epidemiol, 21 (2000), pp. 270-271
[27.]
EMEA doc. ref. EMEA/576176/2009. Available from: http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf [Accessed 2010 Feb 28].
[28.]
S.E. Cosgrove.
The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs.
Clin Infec Dis, 42 (2006), pp. S86-S89
[29.]
Harrison PF, Lederberg J. Institute of Medicine. Antimicrobial drug resistent: Issues and opcions. Institute of Medicine Workshop Report. Washington, DC: Nacional Academy Press; 1998. Available from: http://www.iom.edu/CMS/3783/3924/4564.aspx. [Accessed 2009 Nov 6].
[30.]
N. Namias, L. Samiian, D. Nino, E. Shirazi, K. O’Neill, D. Kett, et al.
Incidence and susceptibility of pathogenic bacteria vary between Intensive Care Units within a Single Hospital: Implications for empiric antibiotic strategies.
J Trauma., 49 (2000), pp. 638-646
[31.]
Available from: http://www.sempsph.com/sempsph/index.php?option=com_content&view=article&id=23:estudio-epine-2008&catid=1:general&Itemid=10. [Accessed 2009 Oct 30].
[32.]
A.I. Hidron, J.R. Edwards, J. Patel, T.C. Horan, D.M. Sievert, D.A. Pollock, et al.
for the National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007.
Infect Control Hosp Epidemiol., 29 (2008), pp. 996-1011
[33.]
IPSE annual report 2006. Available from: http://www.helics.univlyon1.fr/documents/IPSE_Annual_Report_2006.pdf.
[34.]
H. Goossens.
European status of resistance in nosocomial infections.
Chemotherapy, 51 (2005), pp. 177-181
[35.]
M.J. López Pueyo, F. Álvarez Lerma, M. Palomar, P. Olaechea, J.J. Otal, Grupo ENVIN-UCI.
Evolución de los marcadores de multirresistencia en UCI Datos 2005–2008.
Med Intensiva, 33 (2009), pp. 110
[36.]
Comunicado a congreso ICAAC 2008. Lepainteur M. Linezolid resistance in sequential methicillin-resistant Staphylococcus aureus isolates. pg. 108 (abstract C1-188).
[37.]
Comunicado a congreso ICAAC 2008. Revell P. Linezolid nonsusceptible Staphylococcus aureus in three patients with cystic fibrosis receiving prolonged linezolid therapy. Late-breaker pg. 317 (abstract C2-1087 a).
[38.]
De la Torre. Outbreak of linezolid-resistant Staphylococcus aureus in intensive care. Late-breaker. pg. 322 (abstract C2-1835 a). Comunicado a congreso ICAAC 2008.
[39.]
S. Kelly, J. Collins, M. Maguire, C. Gowing, M. Flanagan, M. Donnelly, et al.
An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit.
J Antimicrob Chemother, 61 (2008), pp. 901-907
[40.]
M. Treviño, L. Martínez-Lamas, P.A. Romero-Jung, J.M. Giráldez, J. Álvarez-Escudero, B.J. Regueiro.
Endemic linezolid-resistant Staphylococcus epidermidis in a critical care unit.
Eur J Clin Microbiol Infect Dis, 28 (2009), pp. 527-533
[41.]
A. Valverde, T.M. Coque, L. Garcia-San Miguel, F. Baquero, R. Canton.
Complex molecular epidemiology of extended-spectrumlactamases in Klebsiella pneumoniae: A long-term perspective from a single institution in Madrid.
J Antimicrob Chemother, 61 (2008), pp. 64-72
[42.]
J. Rodríguez-Baño, M.D. López-Prieto, M.M. Portillo, P. Retamar, C. Natera, E. Nuño, On behalf of the SAEI/SAMPAC Bacteraemia Group.
Epidemiology and Clinical Features of Community-Acquired Healthcare Associated and Nosocomial Bloodstream Infections in Tertiary and Community Hospitals.
Clin Microbiol Infect, (2009), pp. 20
[43.]
F. Baquero, E. Cercenado, R. Cisterna, M. de la Rosa, J.A. García-Rodríguez, M. Gobernado, et al.
Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infection in Spain: SMART 2003 study outcomes.
Rev Esp Quimioter, 19 (2006), pp. 51-59
[44.]
J.R. Hernández, A. Pascual, R. Cantón, L. Martínez-Martínez, Grupo de Estudio de Infección Hospitalaria. GEIH.
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-ESBL Project 2002).
Enferm Infecc Microbiol Clin, 21 (2003), pp. 77-82
[45.]
M.A. Díaz, J.R. Hernández, L. Martínez-Martínez, J. Rodríguez-Baño, A. Pascual, Grupo de Estudio de Infección Hospitalaria (GEIH).
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-ESBL project, 2006).
Enferm Infecc Microbiol Clin, 27 (2009), pp. 503-510
[46.]
M.J. Bonten, S. Slaughter, A.W. Ambergen, M.K. Hayden, J. van Voorhis, C. Nathan, et al.
The Role of “Colonization Pressure” in the Spread of Vancomycin-Resistant Enterococci: An Important Infection Control Variable.
Arch Intern Med, 158 (1998), pp. 1127-1132
[47.]
J. Merrer, F. Santoli, C. Appéré-De Vecchi, B. Tran, B. De Jonghe, H. Outin.
Colonization Pressure” and Risk of Acquisition of Methicillin-Resistant Staphylococcus aureus in a Medical Intensive Care Unit.
Infect Control Hosp Epidemiol, 21 (2000), pp. 718-723
[48.]
N. Sadfar, D.G. Maki.
The commonality of risk factors for nosocomial colonization and infection with antimicrobialresistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida.
Ann Intern Med, 136 (2002), pp. 834-844
[49.]
A. Bhalla, N.J. Pultz, A.J. Ray, C.K. Hoyen, E.C. Eckstein, C.J. Donskey.
Antianaerobic antibiotic therapy promotes overgrowth of antibioticresistant, gram-negative bacilli and vancomycinresistant enterococci in the stool of colonized patients.
Infect Control Hosp Epidemiol, 24 (2003), pp. 644-649
[50.]
L. Bernard, P. Vaudaux, A. Vuagnat, R. Stern, P. Rohner, D. Pittet, J. Schrenzel, P. Hoffmeyer, Osteomyelitis Study Group.
Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: lack of emergence of glycopeptide resistance.
Infect Control Hosp Epidemiol., 24 (2003), pp. 650-654
[51.]
T.P. Lodise, P.S. McKinnon, M. Rybak.
Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance.
Infect Control Hosp Epidemiol, 24 (2003), pp. 655-661
[52.]
L. Cordero, L.W. Ayers.
Duration of empiric antibiotics for suspected early-onset sepsis in extremely low birth weight infants.
Infect Control Hosp Epidemiol, 24 (2003), pp. 662-666
[53.]
D.L. Paterson, J.G. McCormack.
More evidence of the benefits of rational antimicrobial use in clinical practice.
Infec Control Hosp Epidemiol, 4 (2003), pp. 642-643
[54.]
L.C. McDonald.
Clostridium difficile: responding to a new threat from an old enemy.
Infect Control Hosp Epidemiol, 26 (2005), pp. 672-675
[55.]
Centers for Disease Control and, Prevention.
Guideline for Hand Hygiene in Health-Care Settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force.
MMWR, 51 (2002), pp. 1-44
[56.]
C.A. Muto, J.A. Jernigan, B.E. Ostrowsky, H.M. Richet, W.R. Jarvis, J.M. Boyce, B.M. Farr.
SHEA. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus.
Infect Control Hosp Epidemiol, 24 (2003), pp. 362-386
[57.]
A.N. Duckro, D.W. Blom, E.A. Lyle, R.A. Weinstein, M.K. Hayden, et al.
Transfer of vancomycin-resistant enterococci via health care worker hands.
Arch Intern Med, 165 (2005), pp. 302-307
[58.]
L.A. Puzniak, T. Leet, J. Mayfield, M. Kollef, L.M. Mundy, et al.
To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci.
Clin Infect Dis, 35 (2002), pp. 18-25
[59.]
S. Blot, P. Depuydt, D. Vogelaers, J. Decruyenaere, J. De Waele, E. Hoste, et al.
Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibioticresistant gram-negative bacteria in an intensive care unit.
Infect Control Hosp Epidemiol, 26 (2005), pp. 575-579
[60.]
P. Depuydt, D. Benoit, D. Vogelaers, G. Claeys, G. Verschraegen, K. Vandewoude.
Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.
Intensive Care Med, 32 (2006), pp. 1773-1781
[61.]
P.O. Depuydt, S.I. Blot, D.D. Benoit, G.W. Claeys, G.L. Verschraegen, K.H. Vandewoude, et al.
Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit.
Crit Care Med, 34 (2006), pp. 653-659
[62.]
E. Papadomichelakis, F. Kontopidou, A. Antoniadou, G. Poulakou, E. Koratzanis, P. Kopterides, et al.
Screening for resistant gramnegative microorganisms to guide empiric therapy of subsequent infection.
Intensive Care Med, 34 (2008), pp. 2169-2175
[63.]
L. Bode, J. Kluytmans, H. Wertheim, D. Bogaers, R. Vandenbroucke-Grauls, R. Roosendaal, et al.
Preventing Surgical-Site Infections in Nasal Carriers of Staphylococcus aureus.
N Engl J Med, 362 (2010), pp. 9-17
[64.]
B. Rubinovitch, D. Pittet.
Screening for methicillin-resistant Staphylococcus aureus in the endemic hospital: what have we learned?.
J Hosp Infect, 47 (2001), pp. 9-18
[65.]
J. Rodríguez-Baño, C. Bischofberger, F. Álvarez-Lerma, A. Asensio, T. Delgado, D. García-Arcal, et al.
y Grupos de Estudio de Infección Hospitalaria (GEIH) y de Infección en el Paciente Crítico (GEIPC) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y Sociedad Española de Medicina Preventiva, Salud Pública e Higiene (SEMPSPH). Vigilancia y control de SARM en los hospitales españoles. Documento de consenso.
Enferm Infecc Microbiol Clin, 26 (2008), pp. 285-298
[66.]
Luis Martínez Martínez, María Eliecer Cano, Ma Ángeles Domínguez, Carmen Ezpeleta Baquedano, Belén Padilla Ortega, Encarnación Ramírez de Arellano. Cultivos de vigilancia epidemiológica de bacterias resistentes a los antimicrobianos de interés nosocomial. Procedimientos en microbiología clínica. 2007. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología clínica. Available from: http://www.seimc.org/documentos/protocolos/microbiologia/.
[67.]
M. Castanheira, R.N. Jones, D.M. Livermore.
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Diagn Microbiol Infect Dis, 63 (2009), pp. 426-433
[68.]
J. Chastre, R. Wunderink, P. Prokocimer, M. Lee, K. Kaniga, I. Friedland.
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Crit Care Med, 36 (2008), pp. 1089-1096
[69.]
M. Montero, J.P. Horcajada, L. Sorlí, F. Álvarez-Lerma, S. Grau, M. Riu, et al.
Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections.
Infection, 37 (2009), pp. 461-465
[70.]
M. Bodí, J. Garnacho.
Pseudomonas aeruginosa: tratamiento combinado frente a monoterapia.
Med Intensiva, 31 (2007), pp. 83-87
[71.]
E. Chamot, E.B. El Amari, P. Rohner, C.H. Van Delden.
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
Antimicrob Agents Chemother, 47 (2003), pp. 2756-2764
[72.]
S.T. Micek, A.E. Lyoyds, D.J. Ritchie, R.M. Reichley, V.J. Fraser, M.H. Kollef.
Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
Antimicrob Agents Chemother, 49 (2005), pp. 1306-1311
[73.]
J. Garnacho-Montero, M. Sa-Borges, J. Sole-Violan, F. Barcenilla, A. Escoresca-Ortega, M. Ochoa, et al.
Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy.
Crit Care Med, 35 (2007), pp. 1888-1895
[74.]
M.L. Joly-Guillou, M. Wolff, J.J. Pocidalo, F. Walker, C. Carbon.
Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem.
Antimicrob Agents Chemother, 41 (1997), pp. 345-351
[75.]
M. Bernabeu-Wittel, A. García-Curiel, C. Pichardo, M.E. Pachón-Ibañez, M.E. Jiménez-Mejias, J. Pachón.
Morphological changes induced by imipenem and meropenm at sub-inhibitory concentrations in Acinetobacter baumannii.
Clin Microbiol Infect, 10 (2004), pp. 931-934
[76.]
C. Urban, E. Go, N. Mariano, B.J. Berger, I. Avraham, D. Rubin, J.J. Rahal.
Effect of sulbactam on infections caused by imipenemresistant. Acinetobacter calcoaceticus Biotype anitratus.
J Infect Dis, 167 (1993), pp. 448-451
[77.]
G.C. Wood, S.D. Hanes, M.A. Croce, T.C. Fabian, B.A. Boucher.
Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia.
Clin Infect Dis, 34 (2002), pp. 1425-1430
[78.]
M.E. Jiménez-Mejías, J. Pachón, B. Becerril, J. Palomino-Nicás, A. Rodríguez-Cobacho, M. Revuelta.
Treatment of multi-drug resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam.
Clin Infect Dis, 24 (1997), pp. 932-935
[79.]
A.S. Levin, A.A. Barone, J. Penço, M.V. Santos, I.S. Marinho, E.A. Arruda, E.I. Manrique, S.F. Costa.
Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
Clin Infect Dis, 28 (1999), pp. 1008-1011
[80.]
A. Montero, J. Ariza, X. Corbella, A. Doménech, C. Cabellos, J. Ayats, F. Tubau, C. Ardanuy, F. Gudiol.
Efficacy of colistin versus b-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.
Antimicrob Agents Chemother, 46 (2002), pp. 1946-1952
[81.]
J. Garnacho-Montero, C. Ortiz-Leyba, F.J. Jiménez-Jiménez, A.E. Barrero-Almodóvar, J.L. García-Garmendia, M. Bernabeu-Wittel, et al.
Treatment of multiresistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem susceptible episodes.
Clin Infect Dis, 36 (2003), pp. 1111-1118
[82.]
N. Markou, H. Apostolakos, C. Koumoudiou, M. Athanasiou, A. Koutsoukou, I. Alamanos, L. Gregorakos.
Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.
Critical Care, 7 (2003), pp. R78-R83
[83.]
R. Reina, E. Estenssoro, G. Sáenz, H.S. Canales, R. Gonzalvo, G. Vidal, et al.
Safety and efficacy of colistin in Acinetobacter and Pseudomonas infecions: a prospective cohort study.
Intensive Care Medicine, 31 (2005), pp. 1058-1065
[84.]
H. Kallel, L. Hergafi, M. Bahloul, A. Hakim, H. Dammak, H. Chelly, et al.
Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study.
Intensive Care Med, 33 (2007), pp. 1162-1167
[85.]
F.G. Rios, C.M. Luna, B. Maskin, A. Saenz Valiente, M. Lloria, S. Gando, et al.
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms.
Eur Respir J, 30 (2007), pp. 307-313
[86.]
D. Hamer.
Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pesudomonas aeruginosa with aerosolized colistin.
Am J Resp Crit Care Med, 162 (2000), pp. 328-330
[87.]
I.P. Korbila, A. Michalopoulos, P.I. Rafailidis, D. Nikita, G. Samonis, M.E. Falagas.
Inhaled colistin as adjunctive to intravenous colistin for the treatment of microbiologically documented VAP: a comparative cohort study.
Clin Microbiol Infect, (2009),
[88.]
P. Fernandez-Viladrich, X. Corbella, L. Corral, F. Tubau, A. Mateu.
Successful treatment of ventriculitis due to carbapenemresistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.
Clin Infect Dis, 28 (1999), pp. 916-917
[89.]
M.E. Jiménez-Mejías, C. Pichardo-Guerrero, F.J. Márquez-Rivas, D. Martín-Lozano, T. Prados, J. Pachón.
Cerebrospinal fluid penetration and phatmacokinetic/parmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 212-214
[90.]
S. Motaouakkil, B. Charra, A. Hachimi, H. Nejmi, A. Benslama, N. Elmdaghri, H. Belabbes, M. Benbachir.
Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.
J Infect, 53 (2006), pp. 274-278
[91.]
M. Bassetti, E. Repetto, E. Righi, S. Boni, M. Diverio, M.P. Molinari, et al.
Colistin and rifampicin in the treatment of multidrugresistant Acinetobacter baumannii infections.
J Antimicrob Chemother, 61 (2008), pp. 417-420
[92.]
L.A. Arroyo, I. Mateos, V. González, J. Aznar.
In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
Antimicrob Agents Chemother, 53 (2009), pp. 1295-1296
[93.]
J.J. Schafer, D.A. Goff, K.B. Stevenson, J.E. Mangino.
Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Pharmacotherapy, 27 (2007), pp. 980-987
[94.]
K.B. Anthony, N.O. Fishman, D.R. Linkin, L.B. Gasink, P.H. Edelstein, E. Lautenbach.
Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.
Clin Infect Dis, 46 (2008), pp. 567-570
[95.]
N.C. Gordon, D.W. Wareham.
A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline.
J Antimicrob Chemother, 63 (2009), pp. 775-780
[96.]
J.R. Hernández, A. Pascual, R. Cantón, L. Martínez-Martínez, Grupo de Estudio de Infección Hospitalaria.GEIH.
Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIHESBL 2000).
Enferm Infecc Microbiol Clin, 21 (2003), pp. 77-82
[97.]
D.L. Paterson, W.C. Ko, A. Von Gottberg, S. Mohapatra, J.M. Casellas, H. Goossens, L. Mulazimoglu, G. Trenholme, K.P. Klugman, R.A. Bonomo, L.B. Rice, M.M. Wagener, J.G. McCormack, V.L. Yu.
Antibiotic Therapy for Klebsiella pneumoniae bacteraemia: implications of production of extend-spectrum b-lactamases.
Clin Infect Dis, 39 (2004), pp. 31-37
[98.]
A.M. Queenan, B. Foleno, C. Gownley, E. Wira, K. Bush.
Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.
J Clin Microbiol, 42 (2004), pp. 269-275
[99.]
J.R. Hernández, L. Martínez-Martínez, R. Cantón, T.M. Coque, A. Pascual, Spanish Group for Nosocomial Infections (GEIH).
Nationwide Study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum B-lactamases in Spain. Spanish Group for Nosocomial Infections (GEIH).
Antimicrob Agents Chemother, 49 (2005), pp. 2122-2125
[100.]
J.R. Hernández, C. Velasco, L. Romero, L. Martínez-Martínez, A. Pascual.
Int J Antimicrob Agents, 28 (2006), pp. 457-459
[101.]
E. Elliot.
In vivo development of ertapenem resistenace in a patient with pneumonia caused by Klebsiella pneumoniae with and extended-spectrum b-lactamase.
Clin Infect Dis, 42 (2006), pp. e95-e98
[102.]
J. Rodríguez-Baño.
Bacteremia due to extended spectrum B-lactamase producing Escherichia coli in the CTX-M Era: A new clinical challenge.
Clin Infect Dis, 43 (2006), pp. 1407-1414
[103.]
M. Souli, F.V. Kontopidou.
In vitro activity of tigecycline against multiple drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.
Antimicrobl Agents Chemother, 50 (2006), pp. 3166-3169
[104.]
M.W. Daly, D.J. Riddle, N.A. Ledeboer, W.M. Dunne, D.J. Ritchie.
Pharmacotherapy, 27 (2007), pp. 1052-1057
[105.]
W.J. Looney, M. Narita, K. Mühlemann.
Stenotrophomonas maltophilia: an emerging opportunist human pathogen.
Lancet Infect Dis, 9 (2009), pp. 312-323
[106.]
S. V aldezate, A. Vindel, E. Loza, F. Baquero, R. Cantón.
Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.
Antimicrob Agents Chemother, 45 (2001), pp. 1581-1584
[107.]
J.L. Gómez-Garcés, B. Aracil, Y. Gil, A. Burillo.
Susceptibility of 228 non-fermenting gram-negative rods to tigecycline and six other antimicrobial drugs.
J Chemother, 21 (2009), pp. 267-271
[108.]
G. Sakoulas, P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering, G.M. Eliopoulos.
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.
J Clin Microbiol, 42 (2004), pp. 2398-2402
[109.]
L.K. Hidayat, D.I. Hsu, R. Quist, K.A. Shriner, A. Wong-Beringer.
Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Arch Intern Med, 23 (2006), pp. 2138-2144
[110.]
A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, V.P. Dimova, et al.
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis, 46 (2008), pp. 193-200
[111.]
P.A. Moise, A. Forrest, S.M. Bhavnani, M.C. Birmingham, J.J. Schentag.
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus.
Am J Health Syst Pharm, 57 (2000), pp. S4-S9
[112.]
M.N. Jeffres, W. Isakow, J.A. Doherty, S.T. Micek, M.H. Kollef.
A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillinresistant Staphylococcus aureus pneumonia.
Clin Ther, 29 (2007), pp. 1107-1115
[113.]
P. Olaechea, J. Garnacho Montero, S. Grau, et al.
Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico.
Enfer Infec Microbiol Clin, 25 (2007), pp. 446-466
[114.]
J. Mensa, J. Barberán, P. Llinares, J. Picazo, E. Bouza, F. Alvarez-Lerma, et al.
Guía para el tratamiento de la infección producida por Staphylococcus aureus resistente a meticilina.
Rev Esp Quimioter, 21 (2008), pp. 234-258
[115.]
R.G. Wunderink, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, M.H. Kollef.
Linezolid vs vancomycin: analysis of two doubleblind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Chest, 124 (2003), pp. 1789-1797
[116.]
M.H. Kollef, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, R.G. Wunderink.
Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.
Intensive Care Med, 30 (2004), pp. 388-394
[117.]
K.M. Itani, J. Weigelt, J.Z. Li, S. Duttagupta.
Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillinresistant Staphylococcus aureus (MRSA).
Int J Antimicrob Agents, 26 (2005), pp. 442-448
[118.]
G. Sakoulas, Y. Golan, K.C. Lamp, L.V. Friedrich, R. Russo.
Daptomycin in the treatment of bacteremia.
Am J Med, 120 (2007), pp. S21-S27
[119.]
D.P. Levine, K.C. Lamp.
Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Am J Med, 120 (2007), pp. S28-S33
[120.]
P.A. Moise, E. Hershberger, M.I. Amodio-Groton, K.C. Lamp.
Safety and clinical outcomes when utilizing high-dose (>or =8mg/kg) daptomycin therapy.
Ann Pharmacother, 43 (2009), pp. 1211-1219
Copyright © 2011. Elsevier y Sociedad Española de Medicina Intensiva, Critica y Unidades Coronarias
